Belatacept
ATC L04AA28 · 6 markets · 6 records
US 1 records · 1 strengths
- 250 mginjectionNULOJIX
GB 1 records · 1 strengths
- 250 mginjectionNulojix 250mg powder for concentrate for solution for infusion vials
AU 1 records · 1 strengths
- 250 mginjectionNULOJIX belatacept (rch) 250mg powder for IV infusion vial
ES 1 records · 1 strengths
- 250 mginjectionNULOJIX
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 NULOJIX
| Strength / form / release | US | GB | AU | ES | EU |
|---|---|---|---|---|---|
| 250 mg injection | NULOJIX | Nulojix 250mg powder for concentrate for solution for infusion vials | NULOJIX belatacept (rch) 250mg powder for IV infusion vial | NULOJIX | |
unknown | NULOJIX |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
1 more strength/form rows are recorded only in EU and are not shown in this table. Hay 1 filas de concentración/forma registradas solo en EU que no se muestran en esta tabla. 另有 1 个规格/剂型仅在 EU 有记录（未在本表显示）。 另有 1 個規格/劑型僅在 EU 有記錄（未在本表顯示）。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.